Literature DB >> 19794125

Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma.

J Yu1, H Deshmukh, R J Gutmann, R J Emnett, F J Rodriguez, M A Watson, R Nagarajan, D H Gutmann.   

Abstract

OBJECTIVE: Independent studies have previously demonstrated that both the HIPK2 and BRAF genes are amplified and rearranged, respectively, in pilocytic astrocytomas (PAs). The purpose of this study was to further investigate the frequency of BRAF and HIPK2 alterations in PAs, the concordance of these events, and their relationship to clinical phenotype.
METHODS: We performed extensive characterization by array-based copy number assessment (aCGH), HIPK2 copy number analysis, and BRAF rearrangement and mutation analysis in a set of 79 PAs, including 9 tumors from patients with neurofibromatosis type 1 (NF1).
RESULTS: We identified 1 of 3 previously identified BRAF rearrangements in 42/70 sporadic PAs. An additional 2 tumors with no rearrangement also exhibited BRAF mutation, including a novel 3-base insertion. As predicted from the genomic organization at this locus, 22/36 tumors with BRAF rearrangement also exhibited corresponding HIPK2 amplification. However, 14/36 tumors with BRAF rearrangement had no detectable HIPK2 gene amplification and 6/20 tumors demonstrated HIPK2 amplification without apparent BRAF rearrangement or mutation. Only 12/70 PAs lacked detectable BRAF or HIPK2 alterations. Importantly, none of the 9 PA tumors from NF1 patients exhibited BRAF rearrangement or mutation.
CONCLUSIONS: BRAF rearrangement represents the most common genetic alteration in sporadic, but not neurofibromatosis type 1-associated, pilocytic astrocytomas (PAs). These findings implicate BRAF in the pathogenesis of these common low-grade astrocytomas in children, and suggest that PAs arise either from NF1 inactivation or BRAF gain of function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19794125      PMCID: PMC2777068          DOI: 10.1212/WNL.0b013e3181c0664a

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  21 in total

1.  Loss of neurofibromatosis 1 (NF1) gene expression in NF1-associated pilocytic astrocytomas.

Authors:  D H Gutmann; J Donahoe; T Brown; C D James; A Perry
Journal:  Neuropathol Appl Neurobiol       Date:  2000-08       Impact factor: 8.090

2.  dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity data.

Authors:  Ming Lin; Lee-Jen Wei; William R Sellers; Marshall Lieberfarb; Wing Hung Wong; Cheng Li
Journal:  Bioinformatics       Date:  2004-02-10       Impact factor: 6.937

3.  Loss of NF1 alleles distinguish sporadic from NF1-associated pilocytic astrocytomas.

Authors:  L Kluwe; C Hagel; M Tatagiba; S Thomas; D Stavrou; H Ostertag; A von Deimling; V F Mautner
Journal:  J Neuropathol Exp Neurol       Date:  2001-09       Impact factor: 3.685

4.  Mutational and expression analysis of the NF1 gene argues against a role as tumor suppressor in sporadic pilocytic astrocytomas.

Authors:  Katharina Wimmer; Markus Eckart; Birgit Meyer-Puttlitz; Christa Fonatsch; Torsten Pietsch
Journal:  J Neuropathol Exp Neurol       Date:  2002-10       Impact factor: 3.685

5.  Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force.

Authors:  R Listernick; D N Louis; R J Packer; D H Gutmann
Journal:  Ann Neurol       Date:  1997-02       Impact factor: 10.422

6.  Optic pathway tumors in children: the effect of neurofibromatosis type 1 on clinical manifestations and natural history.

Authors:  R Listernick; C Darling; M Greenwald; L Strauss; J Charrow
Journal:  J Pediatr       Date:  1995-11       Impact factor: 4.406

7.  Nonrandom chromosomal gains in pilocytic astrocytomas of childhood.

Authors:  F V White; D C Anthony; E J Yunis; N J Tarbell; R M Scott; D E Schofield
Journal:  Hum Pathol       Date:  1995-09       Impact factor: 3.466

Review 8.  Are juvenile pilocytic astrocytomas benign tumors? A cytogenetic study in 24 cases.

Authors:  H Zattara-Cannoni; D Gambarelli; G Lena; H Dufour; M Choux; F Grisoli; A M Vagner-Capodano
Journal:  Cancer Genet Cytogenet       Date:  1998-07-15

9.  Analysis of pilocytic astrocytoma by comparative genomic hybridization.

Authors:  D Sanoudou; O Tingby; M A Ferguson-Smith; V P Collins; N Coleman
Journal:  Br J Cancer       Date:  2000-03       Impact factor: 7.640

10.  Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas.

Authors:  David T W Jones; Sylvia Kocialkowski; Lu Liu; Danita M Pearson; L Magnus Bäcklund; Koichi Ichimura; V Peter Collins
Journal:  Cancer Res       Date:  2008-11-01       Impact factor: 12.701

View more
  43 in total

1.  Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group.

Authors:  Joann L Ater; Tianni Zhou; Emiko Holmes; Claire M Mazewski; Timothy N Booth; David R Freyer; Ken H Lazarus; Roger J Packer; Michael Prados; Richard Sposto; Gilbert Vezina; Jeffrey H Wisoff; Ian F Pollack
Journal:  J Clin Oncol       Date:  2012-06-04       Impact factor: 44.544

2.  BRAF-V600E mutation in pediatric and adult glioblastoma.

Authors:  Sonika Dahiya; Ryan J Emnett; Devon H Haydon; Jeffrey R Leonard; Joanna J Phillips; Arie Perry; David H Gutmann
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 3.  Will kinase inhibitors make it as glioblastoma drugs?

Authors:  Ingo K Mellinghoff; Nikolaus Schultz; Paul S Mischel; Timothy F Cloughesy
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  Gamma Knife treatment of low-grade gliomas in children.

Authors:  Murat Şakir Ekşi; Baran Yılmaz; Akın Akakın; Zafer Orkun Toktaş; Ahmet Cemil Kaur; Mustafa Kemal Demir; Türker Kılıç
Journal:  Childs Nerv Syst       Date:  2015-07-15       Impact factor: 1.475

Review 5.  Pediatric low-grade gliomas: how modern biology reshapes the clinical field.

Authors:  Guillaume Bergthold; Pratiti Bandopadhayay; Wenya Linda Bi; Lori Ramkissoon; Charles Stiles; Rosalind A Segal; Rameen Beroukhim; Keith L Ligon; Jacques Grill; Mark W Kieran
Journal:  Biochim Biophys Acta       Date:  2014-02-28

6.  Analysis of the BRAF(V600E) Mutation in Central Nervous System Tumors.

Authors:  Jae Kyung Myung; Hwajin Cho; Chul-Kee Park; Seung-Ki Kim; Se-Hoon Lee; Sung-Hye Park
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

Review 7.  The molecular biology of WHO grade I astrocytomas.

Authors:  Nicholas F Marko; Robert J Weil
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Something old and something new about molecular diagnostics in gliomas.

Authors:  Craig Horbinski
Journal:  Surg Pathol Clin       Date:  2012-12-01

9.  BRAF alterations in pediatric low grade gliomas and mixed neuronal-glial tumors.

Authors:  Efthymios Dimitriadis; George A Alexiou; Panagiota Tsotsou; Efthymia Simeonidi; Kalliopi Stefanaki; Amalia Patereli; Neofytos Prodromou; Nikolaos Pandis
Journal:  J Neurooncol       Date:  2013-04-24       Impact factor: 4.130

Review 10.  Posttranslational modifications regulate HIPK2, a driver of proliferative diseases.

Authors:  Vera V Saul; M Lienhard Schmitz
Journal:  J Mol Med (Berl)       Date:  2013-04-25       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.